PhotoMedex (Nasdaq: PHMD) and Galderma Laboratories, L.P. have entered
into a co-promotion agreement for Galderma’s photodynamic therapy
application for the treatment of actinic keratoses (“AK”). Under the
terms of the agreement, PhotoMedex’ sales force will promote Galderma’s
drug Metvixia® (methyl aminolevulinate) Cream, 16.8% (“Metvixia”) and
Galderma’s Aktilite® CL128 LED (light-emitting diode) lamp to healthcare
professionals, including dermatologists, plastic surgeons and cosmetic
surgeons throughout the United States. Galderma will provide marketing
support and distribution. The three-year agreement begins in January; no
financial terms have been disclosed.
Actinic keratoses are very common lesions that occur on sun-damaged skin
and are widely considered to be a precursor to squamous cell carcinoma.
Metvixia is a topical porphyrin precursor used in photodynamic therapy.
When applied to actinic keratosis lesions, Metvixia is selectively
absorbed into precancerous cells causing a build-up of endogenous
porphyrins. These endogenous porphyrins are illuminated with the
Aktilite CL128 lamp emitting a narrow output spectrum of red light with
a peak wavelength at 630 nm. Subsequently, a reaction occurs that
results in the destruction of the precancerous cells. Clinical trials in
various countries with the Metvixia PDT system have shown comparable or
better response rates than conventional treatments, such as cryotherapy
or surgery. Metvixia PDT selectively targets precancerous cells so the
surrounding healthy cells are less subjected to the treatment, therein
minimizing scarring and ensuring more acceptable cosmetic outcomes for
patients. In clinical trials, the most commonly reported adverse events
associated with use of Metvixia PDT were contact sensitization,
erythema, pain, burning, and skin discomfort/irritation.